Management of Atrial Fibrillation with Rapid Ventricular Response in Heart Failure

Initial Assessment and Management

The American Heart Association recommends determining if the patient has heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), as this affects medication selection 1, 2
Evaluate for potential reversible causes of AF with RVR, including electrolyte abnormalities and thyroid dysfunction 3

For patients with atrial fibrillation (AF) with rapid ventricular response (RVR) and heart failure, the American College of Cardiology recommends intravenous digoxin or amiodarone as first-line therapy for acute rate control, while beta blockers should be used cautiously in those with decompensated heart failure 1, 2, 4
Beta blockers or nondihydropyridine calcium channel antagonists (diltiazem, verapamil) are recommended as first-line therapy for HFpEF patients 1, 2, 4
A combination of digoxin and a beta blocker is reasonable to control both resting and exercise heart rate 1, 5

For patients with persistent symptoms despite rate control, a rhythm control strategy may be reasonable 1, 2, 4
For patients with AF and RVR causing or suspected of causing tachycardia-induced cardiomyopathy, either AV nodal blockade or a rhythm-control strategy is reasonable 1, 2, 4
Oral amiodarone may be considered when resting and exercise heart rate cannot be adequately controlled using other agents 1, 2, 4
AV node ablation with ventricular pacing is reasonable when pharmacological therapy is insufficient or not tolerated 1, 2, 4

Lenient rate control (resting heart rate <110 bpm) is an acceptable initial approach unless symptoms call for stricter control 5
Assessment of heart rate control during exercise and adjustment of pharmacological treatment is useful in symptomatic patients during activity 1, 2, 4

AV node ablation should not be performed without a prior pharmacological trial to achieve ventricular rate control 1, 2, 4
Always consider anticoagulation based on stroke risk factors regardless of rate control strategy 3, 5

In patients with CHF and COPD who develop AF with RVR, the American College of Cardiology recommends using IV digoxin or IV amiodarone for acute rate control, avoiding beta-blockers and calcium channel blockers due to the combination of decompensated heart failure risk and pulmonary disease 6
If the patient is hemodynamically unstable, the European Heart Journal suggests proceeding immediately to electrical cardioversion 6, 7

The American College of Cardiology recommends IV digoxin as the preferred initial agent for rate control in heart failure without negative inotropic effects, with a Class I, Level B recommendation 6
IV amiodarone is an equally appropriate first-line choice when other measures are unsuccessful or contraindicated, with a Class IIa, Level C recommendation 6

The American College of Cardiology states that beta-blockers should be used with extreme caution in patients with overt congestion, hypotension, or decompensated HFrEF, and should NOT be given with decompensated heart failure (Class III: Harm) 6
Nondihydropyridine calcium channel blockers are contraindicated in decompensated heart failure (Class III: Harm recommendation) 6

If rate control is inadequate with initial therapy, the American College of Cardiology recommends considering adding digoxin to the regimen or using a combination of digoxin and a beta-blocker (once stabilized) to control both resting and exercise heart rate 6
If symptoms persist despite adequate rate control, a rhythm control strategy is reasonable in chronic HF patients who remain symptomatic despite rate control 6